open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

The role of anthracyclines in the treatment of advanced breast cancer — the place of nonpegylated liposomal doxorubicin

Iwona Głogowska, Roman Dubiański, Anna Skrzypczyk, Tadeusz Pieńkowski

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Despite of introducing to the therapy of breast cancer many new cytotoxic and molecularly targeted agents anthracyclines still have strong position in treatment of this type of cancer, both adjuvant treatment and treatment of metastatic disease. The most important side effect that limits the use of anthracyclines is cardiotoxicity. To avoid this the special liposomal form of doxorubicin was introduced to the treatment of metastatic breast cancer. The aim of doxorubicin molecule’s modification was to increase activity of drug in cancer cells and to limit non-specific organ toxicity, especially to decrease toxic effect on myocardium. Liposomal doxorubicin is effective in the treatment of metastatic breast cancer and has low cardiac risk. Combined treatment with liposomal doxorubicin and molecularly targeted therapies has been investigated in recent years.
Onkol. Prak. Klin. 2010; supl. A: A8–A17

Abstract

Despite of introducing to the therapy of breast cancer many new cytotoxic and molecularly targeted agents anthracyclines still have strong position in treatment of this type of cancer, both adjuvant treatment and treatment of metastatic disease. The most important side effect that limits the use of anthracyclines is cardiotoxicity. To avoid this the special liposomal form of doxorubicin was introduced to the treatment of metastatic breast cancer. The aim of doxorubicin molecule’s modification was to increase activity of drug in cancer cells and to limit non-specific organ toxicity, especially to decrease toxic effect on myocardium. Liposomal doxorubicin is effective in the treatment of metastatic breast cancer and has low cardiac risk. Combined treatment with liposomal doxorubicin and molecularly targeted therapies has been investigated in recent years.
Onkol. Prak. Klin. 2010; supl. A: A8–A17
Get Citation

Keywords

advanced breast cancer; anthracyclines; cardiotoxicity; non-pegylated liposomal doxorubicin

About this article
Title

The role of anthracyclines in the treatment of advanced breast cancer — the place of nonpegylated liposomal doxorubicin

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

8-17

Published online

2010-11-22

Keywords

advanced breast cancer
anthracyclines
cardiotoxicity
non-pegylated liposomal doxorubicin

Authors

Iwona Głogowska
Roman Dubiański
Anna Skrzypczyk
Tadeusz Pieńkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl